Krystal Biotech (KRYS) Gross Profit (2023 - 2026)

Krystal Biotech has disclosed Gross Profit across 4 years of filings, most recently posting $110.0 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $110.0 million, up 32.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $392.9 million (up 26.43% YoY), and the FY2025 annual result was $366.1 million, up 35.35% from the prior year.
• Gross Profit came in at $110.0 million for Q1 2026 at Krystal Biotech, up from $100.5 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $110.0 million in Q1 2026 to a low of $8.3 million in Q3 2023.
• The 4-year median for Gross Profit is $83.2 million (2025), against an average of $72.2 million.
• Across the five-year window, Gross Profit jumped 825.92% in 2024 and advanced 16.64% in 2025, its largest moves.
• Krystal Biotech's Gross Profit stood at $39.3 million in 2023, then jumped by 119.41% to $86.2 million in 2024, then rose by 16.64% to $100.5 million in 2025, then grew by 9.48% to $110.0 million in 2026.
• The last three Gross Profit figures came in at $110.0 million (Q1 2026), $100.5 million (Q4 2025), and $93.5 million (Q3 2025), per Business Quant data.